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METHODS
The details of the methodology are described elsewhere in this supplement of Pediatric Critical Care Medicine (2) . Briefly, we searched PubMed, EMBASE, and Cochrane Library from 1980 to December 2015, with an update in May 2017, using a combination of medical subject heading terms and text words to define concepts of RBC transfusion and ABI in children. We searched references from identified articles for additional publications. Two authors reviewed all citations independently. We used a standardized data extraction form to construct evidence tables and graded the evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. A panel of 38 experts from 29 academic institutions in eight countries met over the course of 2 years to develop evidence-based and, when evidence was lacking, expert-based recommendations for RBC transfusion in critically ill children. Three experts coordinated the ABI subgroup. Recommendations developed and supporting literature were reviewed and scored by all panel members, using the Research and Development/UCLA Appropriateness Method. All recommendations reached agreement (> 80%). Final recommendations for RBC transfusion in critically ill children with ABI were divided into two categories: clinical recommendations and research recommendations.
RESULTS
The structured literature search identified 905 citations, of which 90 were selected for full text review. None of the reports yielded results related to the care of pediatrics patients or met the criteria for inclusion in the final data analysis for pediatric recommendations. However, in the case of pediatric sTBI, nine case series were also identified that described a management protocol that included the use of a hemoglobin target, some in the context of optimizing Pbo 2 during treatment of raised intracranial pressure (2-10). Since none of these studies examined a relationship between hemoglobin and any outcome, but merely described that a specific hemoglobin was used in practice, we could not include these data in our summative analysis. That said, it is of note that the thresholds used for transfusion varied and included hemoglobin thresholds of 7.0 g/dL (hematocrit 21%) (11), 9.0 g/dL (10), 10.0 g/dL (hematocrit 30%) (3, 7), 11.0 g/dL (4), and 12.0 g/dL (5) . The most recent of these reports come from 2012 (10) and 2016 (11).
Last, two systematic reviews of the ABI literature in adults were reviewed for comparative evidence (12, 13) . In neurocritically ill adults, there was no significant evidence to confirm or refute a difference in effect between lower and higher hemoglobin groups, that is, 7.0-10.0 versus 9.5-11.5 g/dL (12) . In sTBI, RBC transfusion is frequent, and the thresholds for transfusion varied widely between studies (i.e., 6-10 g/dL) with no evidence of benefit or harm (13) .
Therefore, taking all of the above information together, two clinical recommendations and two research recommendations were developed by the experts and voted on. All recommendations reached agreement (> 80%). 
CLINICAL RECOMMENDATIONS

Rationale
In the absence of data to inform the recommendation for RBC transfusion, the Transfusion and Anemia Expertise Initiative (TAXI) experts took into consideration a number of factors in its determination. The evolution in pediatric sTBI management protocols was critical in formulating these recommendations, with the modern tendency to use 7.0 g/dL as the lowest hemoglobin threshold for transfusion (11) and the evidence from systematic reviews in adults with ABI or sTBI (12, 13) . When taken together, the most parsimonious conclusion was that a pediatric patient with ABI should receive RBC transfusion when hemoglobin is less than 7.0 g/dL, but not when hemoglobin is greater than 10.0 g/dL. There was no evidence to support a definitive recommendation to give a RBC transfusion when the hemoglobin is less than 7.0 g/dL in this population, as the only high-quality randomized controlled trial on thresholds in PICUs was not designed to study the benefit or harm of a restrictive transfusion strategy in pediatric ABI patients (14) . In the range 7.0-10.0 g/dL, the consensus among all TAXI experts is that RBC transfusion can be considered. 
As discussed above, there is limited evidence to guide RBC transfusion practice in children with ABI. Further clarity is needed from informative physiology studies, but more so from welldesigned randomized clinical trials to examine how to best determine the optimal transfusion threshold to improve longterm neurologic functional outcomes. In particular, the primary outcome measure must be a functional neurologic measure considering that mortality or overall organ dysfunction is not optimal in neurocritically ill populations. Also, specific populations need to be studied separately, (e.g., sTBI, stroke) since the physiology of oxygen delivery and extraction by brain tissue differ.
SUMMARY
The clinical evidence to guide RBC transfusion decision-making for children with ABI is almost nonexistent; the guidelines committee has had to examine published management protocols and data from the literature in adults with ABI. Although consensus was reached with very strong agreement on the recommendation to consider RBC transfusion for pediatric ABI patients with a hemoglobin of 7.0-10.0 g/dL and to not use Pbo 2 monitors to guide transfusion decisions, much work remains to answer important questions about the safety and efficacy of RBC transfusion in this patient population.
